May 20, 2011 - Accuray Incorporated announced that 85 percent of European CyberKnife centers are performing prostate stereotactic body radiation therapy (SBRT) to treat localized prostate cancer. There is an increasing trend towards treating prostate cancer patients with a hypofractionated regimen.
"More than 25 percent of our CyberKnife patients are being treated for prostate cancer with further growth anticipated," said Dr. David Feltl, head of the oncology department, Ostrava University Hospital, Ostrava, Czech Republic.
At the Annual Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO) in London, U.K., this growth was supported by strong clinical evidence presented at a symposium focused on prostate cancer co-chaired by Prof. Eric Lartigau, Centre Oscar Lambret, Lille, France, and Prof. Volker Budach, M.D., Ph.D., Charite – Universitatsmedizin Berlin, Germany.
"Offering CyberKnife non-invasive treatments to our patients provides excellent five-year tumor control and very low level of toxicity as recently published in Radiation Oncology 2011," said Prof. Eric Lartigau.
"There is a strong academic interest to further drive prospective randomized clinical evidence for prostate SBRT with the CyberKnife System leading the clinical trend," said Prof. Volker Budach.
For more information: www.accuray.com
March 24, 2026 
